Genzyme/Sanofi-Aventis
On February 16 2011, Genzyme Corporation (Nasdaq: GENZ) confirmed a definitive agreement to be acquired by Sanofi-aventis (NYSE: SNY) for $74.00 per share in cash, or approximately $20.1 billion, plus one Contingent Value Right.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
The Contingent Value Right entitling the holder to receive additional cash payments if specified milestones related to Lemtrada™ are achieved over time or a milestone related to production volumes in 2011 for Cerezyme® and Fabrazyme® is achieved. The CVR will be publicly traded.
The transaction is expected to close early in the second quarter of 2011.
Evercore Partners and J.P. Morgan served as sanofi-aventis' lead financial advisors on the transaction, and Weil, Gotshal & Manges LLP served as its legal counsel. Credit Suisse and Goldman Sachs served as financial advisors to Genzyme. Ropes & Gray LLP served as Genzyme's legal counsel, while Wachtell, Lipton, Rosen & Katz served as legal counsel to Genzyme's independent directors.
View Older Stories
-
Damora Therapeutics names Jennifer Jarrett as CEO, adds board members
-
NervGen hires Shamim Ruff as regulatory chief, Christine McSherry as SVP
-
NodThera names Geoff McDonough as CEO ahead of phase 2 trial results
-
Compass Therapeutics names new commercial and medical officers
-
TYRA appoints Bhavesh Ashar as COO and Heather Faulds as CRO
-
CG Oncology adds Christina Rossi to board, Simone Song resigns
-
Marker Therapeutics adds Kathryn Penkus Corzo to board of directors
-
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry unit
-
KalVista names Bilal Arif COO and Linea Aspesi chief people officer
-
FDA removes safety restrictions for Sanofi thyroid cancer drug
-
Seres Therapeutics names co-CEOs as current chief executive steps down
-
Q32 Bio (QTTB) Appoints Adrien Sipos as Interim Chief Medical Officer
-
Applied Therapeutics Inc. (APLT) Appoints Evan Bailey as Chief Medical Officer
-
Day One Biopharmaceuticals (DAWN) Appoints Michael Vasconcelles, M.D., as Head of Research and Development
-
Charles River Laboratories (CRL) Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
-
Zenas BioPharma (ZBIO) Appoints Lisa von Moltke as Chief Medical Officer
-
Verastem Oncology (VSTM) Appoints Matthew E. Ros as COO
-
Nuvation Bio (NUVB) Appoints Philippe Sauvage as CFO
-
Kura Oncology (KURA) Appoints Michael Vasconcelles to its Board
-
Heron Therapeutics (HRTX) Appoints Brett Fleshman as Chief Business Officer
-
Verve Therapeutics (VERV) Appoints Nia Tatsis and Jodie Morrison to its Board
-
HAVAS HEALTH WELCOMES CATHERINE BRASSINGTON-RICHARDS AS GLOBAL CLIENT DIRECTOR
-
Vicore Expands and Strengthens its Board of Directors
-
Ensoma Appoints Accomplished Company Builder and Product Developer, Jim Burns, Ph.D., as Chief Executive Officer
-
Obsidian Therapeutics Appoints Dana Alexander as Chief Technical Officer
-
Tyra Biosciences (TYRA) Appoints Susan Moran and S. Michael Rothenberg to its Board
-
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
-
Recombinant Proteins Market to Reach USD 5.8 Billion by 2030, Prominent Players Shaping the Industry Landscape
-
Enanta Pharma (ENTA) names Matthew P. Kowalsky as Chief Legal Officer
-
Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
-
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
-
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
-
Brainstorm Cell Therapeutics (BCLI) Announces Management Changes
-
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
-
Cadenza Bio, Inc. Appoints Michael A. Panzara, MD, MPH, to its Board of Directors
-
Upstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership Team
-
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
-
GRO Biosciences Expands Executive Team with Appointment of Biopharma Veteran Tracey Lodie, PhD as Chief Development Officer
-
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
-
Disc Medicine (IRON) Appoints Jean Franchi as CFO, Jonathan Yu as COO
-
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
-
TScan Therapeutics, Inc (TCRX) Appoints Jason A. Amello as CFO
-
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
-
Soleno Therapeutics (SLNO) Announces Leadership Appointments
-
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
-
Laurence Rodriguez, Appointed CEO of GenSight Biologics in December 2023, Joins the Company’s Board of Directors
-
BioCT Welcomes Accomplished Life Science Executives to Board of Directors
-
Domain Therapeutics Strengthens Leadership Team to Spearhead Global Development and North American Expansion as the Leading GPCR Immuno-Oncology Company
-
Calliditas Therapeutics (CALT) Appoints Maria Tornsen as President North America
-
Calliditas Therapeutics appoints Maria Törnsén as President North America

